Lakewood-Amedex Biotherapeutics D
D
LABT
0.37150
USD
-0.17
(-30.75%)
Post Trading·0.38040USD+0.00890(+2.40%)
Last updated: · Delayed 15 min
Volume
293,695
EPS
-6
Div Yield
-
P/E
-0
Market Cap
880,339
Title: Lakewood/Amedex Biotherapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.